Custom Search
|
Tysabri...intravenous infusion.
Natalizumab,[Tysabri] is a humanized monoclonal antibody against the cellular adhesion molecule a4-integrin.
Natalizumab,[Tysabri] is used in the treatment of multiple sclerosis and Crohn's disease. It is co-marketed by Biogen Idec and Elan as Tysabri,
and was previously named Antegren. Natalizumab is administered by intravenous infusion every 28 days.
The drug is believed to work by reducing the ability of inflammatory immune cells to attach to and pass through the cell layers
lining the intestines and blood-brain barrier. Natalizumab has proven effective in treating the symptoms of both diseases, preventing relapse,
vision loss, cognitive decline and significantly improving quality of life in people with multiple sclerosis,
as well as increasing rates of remission and preventing relapse in Crohn's disease.
Natalizumab,[Tysabri] was approved in 2004 by the United States Food and Drug Administration.
It was subsequently withdrawn from the market by its manufacturer after it was linked with three cases of the rare
neurological condition progressive multifocal leukoencephalopathy when administered in combination with interferon beta-1a,
another immunosuppressive drug often used in the treatment of multiple sclerosis.
After a review of safety information and no further deaths, the drug was returned to the US market in 2006 under a special prescription program.
In the European Union, it has been approved only for the treatment of multiple sclerosis.
The information about Tysabri,Natalizumab is edited,
and based on this article
editor: H.m.Hanse copyright in accordance with the GNU licence